{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:04:23Z","timestamp":1790359463762,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03400-6","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:58:01Z","timestamp":1790359081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Major bleeding modifiers in anticoagulated patients with atrial fibrillation and heart failure: a systematic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-876X","authenticated-orcid":false,"given":"Jumpei","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"5","key":"3400_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","volume":"133","author":"R Santhanakrishnan","year":"2016","unstructured":"Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA et al (2016) Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133(5):484\u2013492. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018614","journal-title":"Circulation"},{"issue":"36","key":"3400_CR2","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM et al (2024) 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45(36):3314\u20133414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"issue":"9921","key":"3400_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"issue":"5","key":"3400_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest 138(5):1093\u20131100. https:\/\/doi.org\/10.1378\/chest.10-0134","journal-title":"Chest"},{"issue":"46","key":"3400_CR5","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1093\/eurheartj\/ehv476","volume":"36","author":"EC O\u2019Brien","year":"2015","unstructured":"O\u2019Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE et al (2015) The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 36(46):3258\u20133264. https:\/\/doi.org\/10.1093\/eurheartj\/ehv476","journal-title":"Eur Heart J"},{"issue":"4","key":"3400_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","volume":"58","author":"MC Fang","year":"2011","unstructured":"Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al (2011) A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) Study. J Am Coll Cardiol 58(4):395\u2013401. https:\/\/doi.org\/10.1016\/j.jacc.2011.03.031","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"3400_CR7","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.jtha.2026.04.001","volume":"24","author":"X Wang","year":"2026","unstructured":"Wang X, Pan MM, Wang J, Gu ZC, Zhang C, Lin HW (2026) Identifying risk factors for major bleeding in patients with atrial fibrillation using direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost 24(7):2461\u20132472. https:\/\/doi.org\/10.1016\/j.jtha.2026.04.001","journal-title":"J Thromb Haemost"},{"key":"3400_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3400_CR9","doi-asserted-by":"publisher","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al.(2020)\u00a0Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds.\u00a0JBI Manual for Evidence Synthesis. Adelaide: JBI. https:\/\/doi.org\/10.46658\/JBIMES-20-08","DOI":"10.46658\/JBIMES-20-08"},{"key":"3400_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"3400_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3400_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J statist soft 36:1\u201348","journal-title":"J statist soft"},{"issue":"3","key":"3400_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.112.000143","volume":"6","author":"JJV McMurray","year":"2013","unstructured":"McMurray JJV, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J et al (2013) Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 6(3):451\u2013460. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000143","journal-title":"Circ Heart Fail"},{"issue":"4","key":"3400_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212","volume":"6","author":"S van Diepen","year":"2013","unstructured":"van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W et al (2013) Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 6(4):740\u2013747. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000212","journal-title":"Circ Heart Fail"},{"issue":"9","key":"3400_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/eurjhf\/hft111","volume":"15","author":"J Ferreira","year":"2013","unstructured":"Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA et al (2013) Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 15(9):1053\u20131061. https:\/\/doi.org\/10.1093\/eurjhf\/hft111","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"3400_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/ejhf.595","volume":"18","author":"G Magnani","year":"2016","unstructured":"Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M et al (2016) Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail 18(9):1153\u20131161. https:\/\/doi.org\/10.1002\/ejhf.595","journal-title":"Eur J Heart Fail"},{"issue":"6-7","key":"3400_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ejheart.2007.01.013","volume":"9","author":"JGF Cleland","year":"2007","unstructured":"Cleland JGF, Shelton R, Nikitin N, Ford S, Frison L, Grind M (2007) Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. Eur J Heart Fail 9(6\u20137):730\u2013739. https:\/\/doi.org\/10.1016\/j.ejheart.2007.01.013","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"3400_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/eurjhf\/hft093","volume":"15","author":"BA Mulder","year":"2013","unstructured":"Mulder BA, Van Veldhuisen DJ, Crijns HJGM, Tijssen JGP, Hillege HL, Alings M et al (2013) Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail 15(11):1311\u20131318. https:\/\/doi.org\/10.1093\/eurjhf\/hft093","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"3400_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad280","volume":"25","author":"RB Schnabel","year":"2023","unstructured":"Schnabel RB, Ameri P, Siller-Matula JM, Diemberger I, Gwechenberger M, Pecen L et al (2023) Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry. Europace 25(9):euad280. https:\/\/doi.org\/10.1093\/europace\/euad280","journal-title":"Europace"},{"key":"3400_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf485","author":"B Corica","year":"2025","unstructured":"Corica B, Romiti GF, Proietti M, Boriani G, Olshansky B, Huisman MV et al (2025) Heart failure in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF registry phase III. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf485","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"3400_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/ehf2.13156","volume":"8","author":"G Ambrosio","year":"2021","unstructured":"Ambrosio G, Camm AJ, Bassand JP, Corbalan R, Kayani G, Carluccio E et al (2021) Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF. ESC Heart Fail 8(2):1139\u20131149. https:\/\/doi.org\/10.1002\/ehf2.13156","journal-title":"ESC Heart Fail"},{"issue":"1","key":"3400_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.amjcard.2019.09.035","volume":"125","author":"S Chung","year":"2020","unstructured":"Chung S, Kim TH, Uhm JS, Cha MJ, Lee JM, Park J et al (2020) Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the comparison study of drugs for symptom control and complication prEvention of atrial fibrillation [CODE-AF]). Am J Cardiol 125(1):68\u201375. https:\/\/doi.org\/10.1016\/j.amjcard.2019.09.035","journal-title":"Am J Cardiol"},{"issue":"2","key":"3400_CR23","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ehf2.14550","volume":"11","author":"S Ikeda","year":"2024","unstructured":"Ikeda S, Hiasa KI, Inoue H, Yamashita T, Akao M, Atarashi H et al (2024) Clinical outcomes and anticoagulation therapy in elderly non-valvular atrial fibrillation and heart failure patients. ESC Heart Fail 11(2):902\u2013913. https:\/\/doi.org\/10.1002\/ehf2.14550","journal-title":"ESC Heart Fail"},{"issue":"6","key":"3400_CR24","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/ehf2.12971","volume":"7","author":"G Lemesle","year":"2020","unstructured":"Lemesle G, Ninni S, de Groote P, Schurtz G, Lamblin N, Bauters C (2020) Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry. ESC Heart Fail 7(6):3821\u20133829. https:\/\/doi.org\/10.1002\/ehf2.12971","journal-title":"ESC Heart Fail"},{"issue":"4","key":"3400_CR25","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/ehf2.13941","volume":"9","author":"K Nochioka","year":"2022","unstructured":"Nochioka K, Yasuda S, Sakata Y, Shiroto T, Hayashi H, Takahashi J et al (2022) Prognostic impact of a history of cancer and atrial fibrillation in antithrombotic therapy for chronic heart failure. ESC Heart Fail 9(4):2445\u20132454. https:\/\/doi.org\/10.1002\/ehf2.13941","journal-title":"ESC Heart Fail"},{"issue":"2","key":"3400_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007230","volume":"14","author":"CA Jackevicius","year":"2021","unstructured":"Jackevicius CA, Lu L, Ghaznavi Z, Warner AL (2021) Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes 14(2):e007230. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.120.007230","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"3400_CR27","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.amjcard.2019.02.027","volume":"123","author":"A Mentias","year":"2019","unstructured":"Mentias A, Briasoulis A, Shantha G, Alvarez P, Vaughan-Sarrazin M (2019) Impact of heart failure type on thromboembolic and bleeding risk in patients with atrial fibrillation on oral anticoagulation. Am J Cardiol 123(10):1649\u20131653. https:\/\/doi.org\/10.1016\/j.amjcard.2019.02.027","journal-title":"Am J Cardiol"},{"issue":"2","key":"3400_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2024-002975","volume":"11","author":"NR Jones","year":"2024","unstructured":"Jones NR, Smith M, Lay-Flurrie S, Yang Y, Hobbs FDR, Taylor CJ (2024) Heart failure and major haemorrhage in people with atrial fibrillation. Open Heart 11(2):e002975. https:\/\/doi.org\/10.1136\/openhrt-2024-002975","journal-title":"Open Heart"},{"issue":"1","key":"3400_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ehf2.12365","volume":"6","author":"BK Martinez","year":"2019","unstructured":"Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI (2019) Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. ESC Heart Fail 6(1):10\u201315. https:\/\/doi.org\/10.1002\/ehf2.12365","journal-title":"ESC Heart Fail"},{"issue":"3","key":"3400_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213614","volume":"14","author":"A Amin","year":"2019","unstructured":"Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M et al (2019) Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PLoS ONE 14(3):e0213614. https:\/\/doi.org\/10.1371\/journal.pone.0213614","journal-title":"PLoS ONE"},{"issue":"11","key":"3400_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/clc.22064","volume":"35","author":"PL Hess","year":"2012","unstructured":"Hess PL, Greiner MA, Fonarow GC, Klaskala W, Mills RM, Setoguchi S et al (2012) Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. Clin Cardiol 35(11):649\u2013657. https:\/\/doi.org\/10.1002\/clc.22064","journal-title":"Clin Cardiol"},{"issue":"4","key":"3400_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4022\/jafib.953","volume":"6","author":"ZJ Eapen","year":"2013","unstructured":"Eapen ZJ, Mi X, Fonarow GC, Setoguchi S, Piccini JP, Mills RM et al (2013) Anticoagulation and clinical outcomes in heart failure patients with atrial fibrillation: findings from the ADHERE registry. J Atr Fibrillation 6(4):953. https:\/\/doi.org\/10.4022\/jafib.953","journal-title":"J Atr Fibrillation"},{"issue":"7","key":"3400_CR33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s00380-023-02249-6","volume":"38","author":"J Yamamoto","year":"2023","unstructured":"Yamamoto J, Yamamoto M, Hara H, Hiroi Y (2023) Relation between laxative use and risk of major bleeding in patients with atrial fibrillation and heart failure. Heart Vessels 38(7):938\u2013948. https:\/\/doi.org\/10.1007\/s00380-023-02249-6","journal-title":"Heart Vessels"},{"issue":"5","key":"3400_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/europace\/euaa036","volume":"22","author":"M Samuel","year":"2020","unstructured":"Samuel M, Abrahamowicz M, Joza J, Beauchamp ME, Essebag V, Pilote L (2020) Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure. Europace 22(5):739\u2013747. https:\/\/doi.org\/10.1093\/europace\/euaa036","journal-title":"Europace"},{"issue":"12","key":"3400_CR35","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00392-018-1293-4","volume":"107","author":"JH Prochaska","year":"2018","unstructured":"Prochaska JH, G\u00f6bel S, Nagler M, Kn\u00f6pfler T, Eggebrecht L, Lamparter H et al (2018) Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure. Clin Res Cardiol 107(12):1170\u20131179. https:\/\/doi.org\/10.1007\/s00392-018-1293-4","journal-title":"Clin Res Cardiol"},{"key":"3400_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejim.2025.04.038","volume":"136","author":"G Boriani","year":"2025","unstructured":"Boriani G, Mei DA, Bonini N, Vitolo M, Imberti JF, Romiti GF et al (2025) Chronic kidney disease classification according to different formulas and impact on adverse outcomes in patients with atrial fibrillation: a report from a prospective observational European registry. Eur J Intern Med 136:86\u201394. https:\/\/doi.org\/10.1016\/j.ejim.2025.04.038","journal-title":"Eur J Intern Med"},{"issue":"1","key":"3400_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02950-y","volume":"24","author":"GF Romiti","year":"2025","unstructured":"Romiti GF, Mei DA, Corica B, Proietti M, Boriani G, Olshansky B et al (2025) Cardio-kidney-metabolic complexity in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF registry phase III. Cardiovasc Diabetol 24(1):395. https:\/\/doi.org\/10.1186\/s12933-025-02950-y","journal-title":"Cardiovasc Diabetol"},{"key":"3400_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.106512","volume":"145","author":"DA Mei","year":"2026","unstructured":"Mei DA, Imberti JF, Vitolo M, Romiti GF, Corica B, Mantovani M et al (2026) Cardiovascular-kidney-metabolic domains and impact on antithrombotic treatment, integrated care and clinical outcomes in patients with atrial fibrillation: results from a prospective European registry. Eur J Intern Med 145:106512. https:\/\/doi.org\/10.1016\/j.ejim.2025.106512","journal-title":"Eur J Intern Med"},{"key":"3400_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","volume":"128","author":"DA Mei","year":"2024","unstructured":"Mei DA, Imberti JF, Bonini N, Romiti GF, Corica B, Proietti M et al (2024) Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry. Eur J Intern Med 128:63\u201370. https:\/\/doi.org\/10.1016\/j.ejim.2024.06.022","journal-title":"Eur J Intern Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03400-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:58:02Z","timestamp":1790359082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03400-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":39,"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03400-6","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and informed consent were not required because this study was a systematic review of previously published aggregate data.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}